You are seeing these quotes based on previous browsing related to sectors such as
| Latest | Forecast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% |
| Div Cover | n/a | n/a |
| Op Mrgn | -152.1% | 16.1% |
| ROCE | 0.0% |
| Latest | Forecast | |
|---|---|---|
| P/E | -11.0 | 30.0 |
| PEG | 0.0 | -999,999.0 |
| Price / Revenue | 76.1 | 4.9 |
| Price / Book value | 87.3 |
| Latest | Forecast | |
|---|---|---|
| Revenue | n/a | 251.1% |
| PBT | 0.0% | n/a |
| EPS | 0.0% | -155.4% |
| DPS | n/a | 0.0% |
| Year Ending | Revenue (€m) |
Pre-tax (€m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | 17.91 | -0.91 | €-0.01 | -21.2 | 0.0 | n/a | n/a | 0.0% |
| 2017-12-31 | 17.41 | -1.80 | €-0.03 | -4.7 | 0.0 | n/a | n/a | 0.0% |
| 2018-12-31 | n/a | -1.66 | €-7.85 | 0.0 | 0.0 | n/a | n/a | 0.0% |
| 2019-12-31 | 3.84 | -6.62 | €-0.04 | -1.4 | 0.0 | n/a | n/a | 0.0% |
| Open Orphan subsidiary signs contract to make Covid-19 challenge virus Sharecast News | 10 May |
|---|---|
| Open Orphan makes progress with Covid-19 characterisation study Sharecast News | 25 Mar |
| Open Orphan subsidiary awarded contract with Oxford BioTherapeutics Sharecast News | 09 Mar |
| Exercise of Share Options | 10-May-21 07:15 |
|---|---|
| £3m COVID challenge virus manufacturing contract | 10-May-21 07:00 |
| Result of General Meeting | 29-Apr-21 11:39 |
| Potential demerger of certain non-core assets | 13-Apr-21 07:00 |
| Holding(s) in Company | 31-Mar-21 07:00 |